Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 2/20 | 0.81 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.70 |
| ▸ | MAOB known ✓ | P27338 | 3/20 | 0.60 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 3/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.67 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL52482 | 0.97 | MAOA (0.85) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| Benzene SCHEMBL28170833 | 0.97 | MAOA (0.85) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL27510111 | 0.95 | MAOA (0.81) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| Water SCHEMBL28661260 | 0.95 | MAOA (0.81) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| Ammonia Solution, Strong SCHEMBL7296242 | 0.95 | MAOA (0.81) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| Bromide SCHEMBL5311946 | 0.95 | MAOA (0.81) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| Iodide SCHEMBL6672340 | 0.95 | MAOA (0.81) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| 4-Phenyl-Butylamine SCHEMBL8734597 | 0.92 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| Hydrochloric Acid SCHEMBL4621628 | 0.90 | MAOA (0.91) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| Hydrochloric Acid SCHEMBL5157586 | 0.90 | MAOA (0.91) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059186-A1 | LOW-DIMENSIONAL METAL-HALIDE PEROVSKITES FOR INFRARED, TETRAHERTZ, AND MILLIMETER-WAVE LIGHT DETECTION | YALE UNIVERSITY (US) | 2025-03-20 | — | — | WO | claimed |
| EP-1751095-B1 | SUBSTITUTED CYCLOHEXYLCARBOXYLIC ACID DERIVATIVES | GRUENENTHAL GMBH (DE) | 2014-06-18 | — | — | EP | claimed |
| EP-1897881-A2 | Compounds useful for the treatment of obesity, type II diabetes and CNS disorders | Biovitrum AB (publ) (SE) | 2008-03-12 | — | — | EP | claimed |
| US-7241802-B2 | Substituted cyclohexylcarboxylic acid amide compounds | GRUENENTHAL GMBH (DE) | 2007-07-10 | — | — | US | claimed |
| US-20070105941-A1 | Substituted cyclohexylcarboxylic acid amide compounds | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | claimed |
| EP-1513828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | Biovitrum AB (SE) | 2005-03-16 | — | — | EP | claimed |
| US-20040024210-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-05 | — | — | US | claimed |
| WO-2004000828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | claimed |
| US-20250270158-A1 | PROCESS FOR PREPARING TAPINAROF | Dermavant Sciences GmbH (CH) | 2025-08-28 | — | — | US | disclosed |
| US-12275696-B2 | Process for preparing tapinarof | Dermavant Sciences GmbH (CH) | 2025-04-15 | — | — | US | disclosed |
| WO-2025059186-A1 | LOW-DIMENSIONAL METAL-HALIDE PEROVSKITES FOR INFRARED, TETRAHERTZ, AND MILLIMETER-WAVE LIGHT DETECTION | YALE UNIVERSITY (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-118979011-A | Method for establishing single cell of human pluripotent stem cell | 杭州瑞普晨创科技有限公司 | 2024-11-19 | — | — | CN | disclosed |
| US-20230174445-A1 | PROCESS FOR PREPARING TAPINAROF | Dermavant Sciences GmbH (CH) | 2023-06-08 | — | — | US | disclosed |
| US-11597692-B2 | Process for preparing tapinarof | Dermavant Sciences GmbH (CH) | 2023-03-07 | — | — | US | disclosed |
| EP-0526561-B1 | COMPOSITION FOR TRANSDERMAL PENETRATION OF MEDICAMENTS | MINNESOTA MINING & MFG (US) | 1996-04-03 | — | — | EP | disclosed |
| EP-0672660-A2 | Substituted cyclohexanol-esters, their use to treat illnesses and pharmaceutical preparations | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-09-20 | — | — | EP | disclosed |
| EP-0526561-A1 | COMPOSITION FOR TRANSDERMAL PENETRATION OF MEDICAMENTS. | MINNESOTA MINING & MFG (US) | 1993-02-10 | — | — | EP | disclosed |
| US-5149719-A | Aqueous solutin of lower alcohol and higher alcohol tosaturate composition | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-09-22 | — | — | US | disclosed |
| WO-1991016930-A1 | COMPOSITION FOR TRANSDERMAL PENETRATION OF MEDICAMENTS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1991-11-14 | — | — | WO | disclosed |
| CN-1054418-A | For with relate to (S)-go improvement of first fluoxetine | LILLY CO ELI (US) | 1991-09-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174445-A1 | PROCESS FOR PREPARING TAPINAROF | TALDO1, TTR, CYP8B1 | MAOA 3718/4885HTR2A 783/4885MAOB 1822/4885 |
| US-12275696-B2 | Process for preparing tapinarof | TALDO1, TTR, CYP8B1 | MAOA 3718/4885HTR2A 783/4885MAOB 1822/4885 |
| US-20040024210-A1 | New compounds | SULT1E1, SULT2A1, SULT1A1 | MAOA 1344/4885HTR2A 1162/4885MAOB 206/4885 |
| US-20250270158-A1 | PROCESS FOR PREPARING TAPINAROF | TALDO1, TTR, CYP8B1 | MAOA 3718/4885HTR2A 783/4885MAOB 1822/4885 |
| US-20070105941-A1 | Substituted cyclohexylcarboxylic acid amide compounds | OPRL1, OPRK1, HCAR1 | MAOA 31/4885HTR2A 23/4885MAOB 34/4885 |
| US-11597692-B2 | Process for preparing tapinarof | TALDO1, TTR, CYP8B1 | MAOA 3718/4885HTR2A 783/4885MAOB 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.